
## UNCOVER THE UNIMET NEEDS IN HIGH-RISK NMBC1

While single-agent BCG is the standard of care, more patients may experience recurrence and progression than expected. 1-3

Register for updates, news and information at NMIBCUnmetNeeds.com

See next page for more information on high-risk, non-muscle-invasive bladder cancer.






## MORE PATIENTS MAY EXPERIENCE RECURRENCE AND PROGRESSION THAN EXPECTED<sup>1</sup>




of patients with high-risk NMIBC may experience recurrence 1 year after single-agent BCG treatment.1



of patients with high-risk NMIBC may experience disease progression to MIBC within 48 months of diagnosis.1

## Delaying progression is critical



5-year relative survival rates decrease by

89% once bladder cancer has metastasized4

## Interested in learning more about high-risk NMIBC?

Read more about recurrence and progression in high-risk NMIBC at NMIBCUnmetNeeds.com

BCG=bacillus Calmette-Guérin; MIBC=muscle-invasive bladder cancer; NMIBC=non-muscle-invasive bladder cancer.

References: 1. Shore ND, Redorta JP, Robert G, et al. Non-muscle-invasive bladder cancer: An overview of potential new treatment options. Urol Oncol. 2021;39(10):642-663. 2. Holzbeierlein J, Bixler BR, Buckley DI, et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline: 2024 amendment. J Urol. 2024. Published online ahead of print January 24, 2024. doi:10.1097/JU.000000000003846 3. Gontero P, Comperat E, Dominguez Escrig JL, et al. EAU guidelines on non-muscle-invasive bladder cancer (TaT1 and CIS). Presented at the EAU Annual Congress Milan. Milan, Italy; March 10-13, 2023.

4. National Cancer Institute: Surveillance, Epidemiology, and End Results (SEER) Program. Cancer stat facts: bladder cancer. Accessed November 28, 2023. https://seer.cancer.gov/statfacts/html/urinb.html

